339362-68-4

Basic information

• Product Name: 3-AMINOCYCLOPENTANONE
• Synonyms: 3-AMINOCYCLOPENTANONE
• CAS NO: 339362-68-4
• Molecular Formula: C5H9NO
• Molecular Weight: 99.1321
• Mol File: 339362-68-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-AMINOCYCLOPENTANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINOCYCLOPENTANONE(339362-68-4)
• EPA Substance Registry System: 3-AMINOCYCLOPENTANONE(339362-68-4)

Safety Data

• Hazardous Substances Data: 339362-68-4(Hazardous Substances Data)

Usage

General Description

3-Aminocyclopentanone is a chemical compound with the molecular formula C5H9NO. It is a cyclic amine and ketone, containing a five-membered ring with an amino group and a carbonyl group. 3-AMINOCYCLOPENTANONE is used in organic synthesis to prepare various heterocyclic compounds and pharmaceuticals. It can also undergo various chemical reactions, such as reduction, acylation, and alkylation, making it a versatile building block in the field of medicinal and organic chemistry. Additionally, 3-aminocyclopentanone has potential for applications in the development of new materials and as a key intermediate in the synthesis of complex organic molecules.

Upstream product

• 1003-03-8 Cyclopentamine 
• 57090-91-2 1,4-dioxa-spiro[4.4]non-6-ylamine 
• 25084-39-3 C₆H₁₀Cl₂N₂O 
• 120-92-3 cyclopentanone 
• 99440-98-9 2-hydroxycyclopentanone 
• 1056246-36-6 2-bromocyclopentanone 

Downstream Products

• 31579-41-6 1,2,3,5,6,7-hexahydrodicyclopentapyrazine 

Relevant articles and documents

Ligustrazine-fused cyclic compound and medicine composition thereof, as well as application in medicine thereof

The invention discloses a ligustrazine-fused cyclic compound and a medicine composition thereof and application in a medicine. The ligustrazine-fused cyclic compound has the following structural general formula I: as shown in the specification. The medicine composition is a medicinal active component for the ligustrazine-fused cyclic compound and a pharmaceutically acceptable carrier, an excipient, a diluent, an adjuvant, a medium or a combination thereof; the ligustrazine-fused cyclic compound and the medicine composition can be used for preventing or treating cardiovascular and cerebrovascular diseases, digestive system diseases, respiratory diseases, the alzheimer's disease, kidney diseases and complications of the above-mentioned diseases due to thrombus and excessive free radicals. The ligustrazine-fused cyclic compound disclosed by the invention has an extremely good inhibition effect on in vitro ADP (adenosine diphosphate)-induced platelet aggregation; meanwhile, compared with the pharmacokinetic property of ligustrazine serving as a female parent, the pharmacokinetic property of the ligustrazine-fused cyclic compound in the body of a rat is obviously improved.